Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression: (Consensus Statement)
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To provide expert recommendations for the safe and effective application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder (MDD). PARTICIPANTS: Participants included a group of 17 expert clinicians and researchers with expertise in the clinical application of rTMS, representing both the National Network of Depression Centers (NNDC) rTMS Task Group and the American Psychiatric Association Council on Research (APA CoR) Task Force on Novel Biomarkers and Treatments. EVIDENCE: The consensus statement is based on a review of extensive literature from 2 databases (OvidSP MEDLINE and PsycINFO) searched from 1990 through 2016. The search terms included variants of major depressive disorder and transcranial magnetic stimulation. The results were limited to articles written in English that focused on adult populations. Of the approximately 1,500 retrieved studies, a total of 118 publications were included in the consensus statement and were supplemented with expert opinion to achieve consensus recommendations on key issues surrounding the administration of rTMS for MDD in clinical practice settings. CONSENSUS PROCESS: In cases in which the research evidence was equivocal or unclear, a consensus decision on how rTMS should be administered was reached by the authors of this article and is denoted in the article as "expert opinion." CONCLUSIONS: Multiple randomized controlled trials and published literature have supported the safety and efficacy of rTMS antidepressant therapy. These consensus recommendations, developed by the NNDC rTMS Task Group and APA CoR Task Force on Novel Biomarkers and Treatments, provide comprehensive information for the safe and effective clinical application of rTMS in the treatment of MDD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Repetitive transcranial magnetic stimulation (rTMS) is an effective method used in clinical practice for treating patients with MDD. 408”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [408]
In the citing paper
“Most clinical rTMS treatments for MDD occur daily (one rTMS session per day) and are applied using scalp-based targeting of DLPFC. These standard treatments are only modestly effective, even in the general MDD population (17, 24–31).”
In the citing paper
“rTMS of the left side of the dorsolateral prefrontal cortex (DLPFC) at 10 Hz is a well-tolerated, evidence-based treatment for TRD.5”
In the citing paper
“While this intensity is consistent with current recommendations for standard rTMS,5 there is no current consensus on the optimal intensity for TBS and other studies have used lower intensities.12”
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Rossi, S., Hallett, M., Rossini, P. M., & Pascual-Leone, A. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.08.016 · Cited by 5,367
NON-INVASIVE MAGNETIC STIMULATION OF HUMAN MOTOR CORTEX
Barker, A. T., Jalinous, R., & Freeston, I. L. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92413-4 · Cited by 4,460
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Wassermann, E. M. (1998) · Electroencephalography and Clinical Neurophysiology/Evoked Potentials Section · doi:10.1016/s0168-5597(97)00096-8 · Cited by 2,293
Lefaucheur, J.-P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., et al. (2014) · Clinical Neurophysiology · doi:10.1016/j.clinph.2014.05.021 · Cited by 2,119
O’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.018 · Cited by 1,910
Self-citationUsing the International 10-20 EEG System for Positioning of Transcranial Magnetic Stimulation
Herwig, U., Satrapi, P., & Schönfeldt-Lecuona, C. (2003) · Brain Topography · doi:10.1023/b:brat.0000006333.93597.9d · Cited by 1,098
George, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092 · cited 1×
“…magnetic stimulation device package insert as well as in the US Food and Drug Administration (FDA) 510k application material. b In the study by George et al,10 patients underwent head magnetic resonance imaging with fiducials (vitamin E capsules), which resulted in 33.2% of patients having…”
BackgroundSelf-citation
Cited by
Items 401–500 of 690
JIANG, L., Lingchuan, N. I. U., Yule, W. A. N. G., Baotong, Y. A. N. G., Hao, L. I., & Jiani, L. I. (2021) · Rehabilitation Medicine · doi:10.3724/sp.j.1329.2021.06003 · Cited by 4
Hopman, H. J., Chan, S. S. M., Chu, C. W., Lu, H., Tse, C., Chau, S. W. H., LAM, L. C. W., Mak, A. D. P., & Neggers, S. F. W. (2021) · Data in Brief · doi:10.1016/j.dib.2021.107264 · Cited by 4
“…or with a contraindication for the use of functional Magnetic Resonance Imaging (fMRI, e.g. pacemakers, metal implants, pregnancy; for details refer to [4] ) and repetitive Transcranial Magnetic Stimulation (rTMS, e.g. history of seizures/epilepsy; for details refer to [5] were also excluded).”
BackgroundReply: Variability in motor threshold
Cotovio, G., Oliveira-Maia, A. J., Paul, C., Viana, F. F., da Silva, D. R., Seybert, C., Stern, A. P., Pascual‐Leone, Á., & Press, D. Z. (2021) · Brain stimulation · doi:10.1016/j.brs.2021.09.012 · Cited by 5
“Such evidence lead to the suggestion by TMS Clinical Consensus that stimulation should be performed at 100-120% of MT in the context of rTMS treatment for depression (6).”
Zhang, J., Raya, J., Morfini, F., Urban, Z., Pagliaccio, D., Yendiki, A., Auerbach, R. P., Bauer, C. C. C., & Whitfield, S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.22.504796 · Cited by 4
“By comparison, randomized controlled clinical trials for TMS – where treatment target is typically not functionally localized – demonstrates a response rate between 15%-37% and a remission rate between 14%-30% (79).”
Special Issue: Update on Neural Oscillations in Neuropsychiatric Disorders
Güntekin, B., & O’Donnell, B. F. (2023) · Clinical EEG and Neuroscience · doi:10.1177/15500594231181523 · Cited by 4
Velasco-Mérida, M., Lázaro, M., Duncan, J. S., Alarcón, G., Stavropoulos, I., & Valentín, A. (2024) · Seizure · doi:10.1016/j.seizure.2024.10.018 · Cited by 2
“For instance, in current clinical practice, it plays a role in the treatment of major depression [4].”
Baldi, S., Chiulli, N., Palm, S. T., Frandsen, S. B., Pell, G. S., Zibman, S., Rodriguez-Ponde, J., Brown, J. C., & Siddiqi, S. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02157-5 · Cited by 4
“That said, targeting more posterior regions could increase seizure risk due to closer proximity to the motor cortex [22].”
Ding, J., Zhang, J.-K., Zhao, F.-F., Chen, M., Lin, Z.-Y., & Chen, C. (2025) · Annals of General Psychiatry · doi:10.1186/s12991-025-00595-5 · Cited by 6
Parkington, K. B., Janssen‐Aguilar, R., Lee, G. H., Rueda, A., Adamsahib, F., Al-Hassan, M., Famuditimi, S., Menzies, P. J. C., Lin, Q., Lou, W. Y. W., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333484 · Cited by 3
“With repeated treatments, the magnetic pulses change the neuronal activity and pathways between brain cells, returning the brain to typical functioning [12].”
Shao, Y., Zhou, Z., Mao, J., Xu, P., Luo, Y., Yu, F., & Wang, S. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121273 · Cited by 3
Caola, L., Sullivan, C. R. P., Widge, A. S., Cabrera, L. Y., & Wilson, S. (2026) · Transcranial magnetic stimulation . · doi:10.1016/j.transm.2026.100206 · Cited by 3
Wan, L., Chen, Y., Zhang, Q., He, S., Ye, Q., Wang, E., Yang, T., & Xie, W. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02603-8 · Cited by 3
“Although non-invasive, TMS requires frequent sessions (typically 4 – 6 weeks, multiple times weekly), imposing high demands on patients in terms of time and resources, with notable recurrence rates 5 .”
Zhu, Y., Liao, L., Gao, S.-H., Tao, Y. K., Huang, H., Fang, X., Yuan, C., & Gao, C.-Y. (2024) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.40 · Cited by 4
“In each session, the 1 Hz ‐ rTMS protocol consisted of 600 stimuli at a frequency of 1 Hz with an intensity of 90% of RMT.”
InfluentialTian, S., Xiao, Y., Deng, X., & Zhang, W. (2024) · ALPHA PSYCHIATRY · doi:10.5152/alphapsychiatry.2024.231442 · Cited by 3
Ye, S. J., Lu, L., Tan, X. W., & Tor, P. C. (2024) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202496 · Cited by 4
Cabrera, L. Y., Bluhm, R. L., McCright, A. M., & Achtyes, E. D. (2024) · Neuroethics · doi:10.1007/s12152-024-09573-2 · Cited by 5
“More recently, repetitive transcranial magnetic stimulation (rTMS) has been approved as a safe and effective treatment for TRD [5, 6].”
Kujovic, M., Bahr, C., Riesbeck, M., Benz, D., Deiß, M., Margittai, Z., Henges, S., Reinermann, D., Plewnia, C., & Meisenzahl, E. M. (2025) · Borderline Personality Disorder and Emotion Dysregulation · doi:10.1186/s40479-025-00278-3 · Cited by 3
Dotson, V. M., Szymkowicz, S. M., Kim, J. U., & McClintock, S. M. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0159-4 · Cited by 4
Self-citationKeller, C. J., Bhati, M. T., Downar, J. H., & Etkin, A. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371501.lr30 · Cited by 2
Engelke, C., Jänner, M., Cordes, J., Ehringfeld, I., Klieser, L., & Kujovic, M. (2020) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh190925042e · Cited by 3
“Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and safe treatment option for patients with treatment resistant depression in adulthood [1, 2].”
BackgroundResultRhythmic transcranial magnetic stimulation in the treatment of resistant depression in schizophrenia
Николаевич, П. А., Лебедева, И. С., Tikhonov, D. V., & Каледа, В. Г. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202112105299 · Cited by 3
Alaghband‐Rad, J., Motamed, M., Khazaeipour, Z., & Farhadbeigi, P. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2021.3369.1 · Cited by 2
Potter, A. R., Hallal-Peche, F., Stavropoulos, I., Price, L. E., Jiménez‐Jiménez, D., Freigang, S., Selway, R., Rosenzweig, I., Lázaro, M., Alarcón, G., et al. (2023) · Brain stimulation · doi:10.1016/j.brs.2023.01.836 · Cited by 3
“rTMS is a non-invasive technique shown to be safe for depression and other psychiatric disorders [5].”
MethodImpact of psychiatric comorbidities on the treatment of epilepsies in adults
Mula, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2250558 · Cited by 4
“rTMS is FDA approved for depression [55] and a specific protocol is available [43].”
Apostol, M., Jordan, T. R., Leuchter, A. F., & Petersen, N. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00154-5 · Cited by 5
“The widely available figure-eight-shaped coils have been approved by the US Food and Drug Administration (FDA) as an effective intervention for treatment-refractory depression, among other indications 38–40 .”
Schwendner, M. J., Schroeder, A., Job, K., Meyer, B., Ille, S., & Krieg, S. M. (2024) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2024.110062 · Cited by 3
“The main stimulation target addressed is the dorsolateral prefrontal cortex (McClintock et al., 2018).”
BackgroundXu, Q., Liang, R., Gao, J., Fan, Y., Dong, J., Wang, L., Zheng, C., Yang, J., & Ming, D. (2024) · Life Sciences in Space Research · doi:10.1016/j.lssr.2024.04.001 · Cited by 4
Chen, J., Chen, Z., Zhang, Y., Fan, X., Zhang, C., Zhu, J., Song, C., Zhang, S., Zhang, D., Tang, L., et al. (2024) · Addiction Biology · doi:10.1111/adb.13425 · Cited by 7
“37 rTMS is considered a safe, non-invasive neurostimulation therapy for depression treatment, even during pregnancy 38 or among elderly patients.”
Recognition and management of treatment-resistant depression
Ma, C., & Strelow, B. (2024) · JAAPA · doi:10.1097/01.jaa.0000000000000163 · Cited by 3
A case of treatment-resistant depression in an older adult and a discussion of treatment options
Pope, E., Muthukrishnan, S., Phillips, J., & Phillips, S. M. (2021) · BJPsych Bulletin · doi:10.1192/bjb.2021.105 · Cited by 3
Conroy, S. K., & Holtzheimer, P. E. (2019) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2019.10.002 · Cited by 4
Taylor, S. F., Lee, T. G., Jonides, J., Tso, I. F., & Hernández-García, L. (2020) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20200011 · Cited by 4
Self-citationMusic combined with Transcranial Magnetic Stimulation for the treatment of depression
Mania, I., & Kaur, J. (2020) · Music and Medicine · doi:10.47513/mmd.v12i4.750 · Cited by 4
Combining invasive and noninvasive brain stimulation
Siddiqi, S., & Fox, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821861-7.00024-5 · Cited by 3
A Pilot Clinical Trial of Repetitive Transcranial Magnetic Stimulation in Mild Cognitive Impairment
Esmaeili, S., Abbasi, M. H., Malekdar, E., Joghataei, M. T., & Mehrpour, M. (2020) · Journal of Neurology Research · doi:10.14740/jnr622 · Cited by 3
“Applying repetitive transcranial magnetic stimulation (rTMS) over the prefrontal cortex is a non-invasive method which has shown desirable therapeutic effects in a wide range of different neurologic disorders including major depression, neuropathic pain, post-stroke neurorehabilitation, as well as multiple sclerosis (…”
MethodRao, J., Hu, G., Yang, W., Yu, J., Xue, C., Li, T., & Chen, J. (2021) · Journal of Neurolinguistics · doi:10.1016/j.jneuroling.2021.100991 · Cited by 3
Hutnyan, M., & McClintock, S. M. (2025) · Transcranial Magnetic Stimulation · doi:10.1016/j.transm.2025.100088 · Cited by 2
Self-citationLi, Z., Zhang, Y.-W., Yang, H.-R., Ren, Y.-Q., Wu, H., Zhang, M.-Y., Zhang, S., Jiao, Y., Yu, W., Xiao, J., et al. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i4.104600 · Cited by 2
“The Food and Drug Administration (FDA) approved TMS in 2008 for treating MDD clinically[7].”
Changizi, M., Rashidi, S., & Zolfagharzadeh-Kermani, M. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.107921 · Cited by 2
Li, W., Yin, Y., You, Z., Zhang, M., Wang, C., Lan, X., Mai, S., Zhang, F., Hu, Z., Liu, G., et al. (2025) · General Psychiatry · doi:10.1136/gpsych-2024-101749 · Cited by 4
Cheng, C., Jeng, J., Chen, M., Chang, W., Liu, M., Lin, W., Tsai, S., Bai, Y., Su, T., & Li, C. (2025) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.70111 · Cited by 3
Luciani, K. R., Schmid, L., Carroll, B., Sebastian, A., Vila‐Rodriguez, F., & Schütz, C. G. (2025) · CNS Spectrums · doi:10.1017/s1092852925100308 · Cited by 2
Yang, P., Li, L., Zhang, R., & Li, H. (2025) · Journal of International Medical Research · doi:10.1177/03000605251359613 · Cited by 3
“29 rTMS was approved by the US Food and Drug Administration in 2008 as a treatment for TRD. 30 Evidence from meta-analyses suggests that rTMS had a largely beneficial effect on patients with TRD, with significant improvement in depressive severity.”
TMS targeting using MRI-free head modeling
Valter, Y., Truong, D. Q., Kawasumi, Y., Bikson, M., & Datta, A. (2025) · Transcranial magnetic stimulation . · doi:10.1016/j.transm.2025.100188 · Cited by 4
Trajectories of response to bilateral rTMS in late-life depression
Adler, E., Blumberger, D. M., Chen, X., Lee, H. H., Nestor, S. M., Downar, J. H., Mulsant, B. H., Rajji, T. K., Noda, Y., Daskalakis, Z. J., et al. (2025) · Brain stimulation · doi:10.1016/j.brs.2025.10.020 · Cited by 4
Wernecke, E., Ragaban, F., Rosenquist, P. B., Jaganathan, N., Healy, W. J., & Fabbro, E. D. (2025) · Cancers · doi:10.3390/cancers17223628 · Cited by 2
“Given a large body of work demonstrating efficacy of rTMS in depression [46], one might expect a concomitant benefit for patients with CIPN and mood symptoms.”
Lu, C. T., Tian, L., Wei, Z., Jiang, Y., Shao, M., Zhu, Y., & Wu, L. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121330 · Cited by 2
Borodulina, I., Gerasimenko, M., Kotova, O., Павлова, С. В., & Zaytseva, T. N. (2026) · Bulletin of Rehabilitation Medicine · doi:10.38025/2078-1962-2026-25-1-40-52 · Cited by 1
Poststroke anxiety and depression: epidemiology, mechanisms, and management strategies
Xie, Y., Wang, D., Shi, Q., Zhou, L., & Ai, T. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1756085 · Cited by 4
Inflammation in treatment-resistant depression: From mechanisms to therapeutics
Wu, S., Gao, X., Zhou, Y., Lin, Z., Chen, C. H., Luo, J., Liu, X., Lin, L., 邵红伟, & Liu, S. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111953 · Cited by 3
González, M., Osama, T., Vandekar, S., Hur, K., Brown, J. H., & Ward, H. B. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122233 · Cited by 2
Sheh, E. G., & Morrison, T. E. (2021) · Journal of Ect · doi:10.1097/yct.0000000000000783 · Cited by 2
Chapter 30. Brain Stimulation Therapies
Keller, C. J., Bhati, M. T., Downar, J. H., & Etkin, A. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372980.lr30 · Cited by 3
Poydasheva, A. G., Sinitsyn, D. O., Bakulin, I. S., Suponeva, N. A., & Пирадов, М. А. (2022) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2022-4-12-19 · Cited by 2
Jampel, J. D., Quinn, M. J., Catalano, J. L., Benca‐Bachman, C. E., Brick, L. A. D., Philip, N. S., Swift, R. M., & McGeary, J. E. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-066175 · Cited by 2
Dam, J. M. V., Graetz, L. J., Pitcher, J. B., & Goldsworthy, M. R. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148359 · Cited by 3
Association between Mood and Sensation Seeking Following rTMS
Kumpf, U., Soldini, A., Burkhardt, G., Bulubas, L., Dechantsreiter, E., Eder, J., Padberg, F., & Palm, U. (2023) · Brain Sciences · doi:10.3390/brainsci13091265 · Cited by 2
“Non-invasive brain stimulation techniques like repetitive transcranial magnetic stimulation (rTMS) are used in clinical trials and in clinical practice for the treatment of mood disorders like major depressive disorder (MDD) [1–3].”
Harvey, A. J., Madden, S., Rodgers, A., Bull, M., Chatterton, M. L., Hadži-Pavlović, D., Loo, C. K. A., & Martin, D. M. (2023) · Journal of Eating Disorders · doi:10.1186/s40337-023-00940-7 · Cited by 2
“A taper period over the following 4 weeks is consistent with clinical recommendations for rTMS [59] and has been designed to coincide with participants attending the hospital for day patient programs, 2 days per week, or continuing in outpatient care following discharge from the inpatient program.”
BackgroundMethodLu, H., Wang, Y., Shen, D.-W., Ruan, J.-G., Lu, J.-M., Wang, L.-L., Song, Y., Fan, J., Li, D., Shi, L.-J., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1226777 · Cited by 3
Kabar, M., Lopez-Chau, L., & Araujo-Banchon, W. J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104013 · Cited by 2
Chatterton, M. L., Lee, Y. Y., Le, L. K., Nichols, M. S., Carter, R., Berk, M., & Mihalopoulos, C. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.04.075 · Cited by 3
Qiao, M.-X., Yu, H., & Li, T. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.06.023 · Cited by 3
Franzen, V., Gruber, N., Klußmann, S., Schoster, A., & May, A. (2024) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.17194 · Cited by 2
Selected Abstracts from the 2024 International Neuroethics Society Annual Meeting
Bissette, H. L., Cecchini, D., Sterner, R., Eskander, E., & Dubljević, V. (2024) · AJOB Neuroscience · doi:10.1080/21507740.2024.2404598 · Cited by 2
Bishay, A. A. E. D., Guo, A., Desai, R., Mushinski, S., Au, A., Swenson, A. J., Iacoboni, M., Bystritsky, A., & Spivak, N. M. (2024) · NeuroSci · doi:10.3390/neurosci5040038 · Cited by 3
Esmaeelzadeh, S., Mahmood, R., & Masood, A. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104311 · Cited by 2
Treatment Advances in Perinatal Depression: Innovations and Promising Approaches
Kendall-Tackett, K. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247744 · Cited by 4
Tseng, P., Zeng, B., Hsu, C., Liang, C., Carvalho, A. F., Brunoni, A. R., Stubbs, B., Su, K.-P., Wu, Y.-C., Wu, Y.-C., et al. (2025) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2025.110290 · Cited by 3
Pilisi, R., Tényi, T., Büki, A., Kovács, N., Zemplényi, A., Sebestyén, G., Osváth, P., Fekete, S., & Vörös, V. (2019) · Orvosi Hetilap · doi:10.1556/650.2020.31611 · Cited by 2
“[19] Shawn M, Irving MR, Linda LC, et al.”
Neurostimulation Approaches in the Treatment of Severe Anorexia Nervosa
Baker, A. (2020) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2003069 · Cited by 2
Transcranial magnetic stimulation and depression
Duncan, C., Shipman, B., Salvacion, C., Jenkins, V., & Richards, S. (2021) · The Nurse Practitioner · doi:10.1097/01.npr.0000724492.63143.cc · Cited by 2
“Patients receive TMS treatment 5 days per week for 4 to 6 weeks depending on their response to treatment.(6)”
BackgroundMethodInfluentialPospelova, M. L., Kasumova, A. A., Fionik, O. V., Alekseeva, T. M., Samochernykh, K. A., & Krasnikova, V. V. (2021) · Современные проблемы науки и образования · doi:10.17513/spno.30631 · Cited by 2
Cognitive Control Deficits in Depression: A Novel Target to Improve Suboptimal Outcomes in Childhood
Oliveira, J. S., Manning, M. C., & Kavanaugh, B. C. (2021) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20090236 · Cited by 2
Wang, A. C., Nikolin, S., Moffa, A. H., Loo, C. K. A., & Martin, D. M. (2021) · Experimental Brain Research · doi:10.1007/s00221-021-06233-2 · Cited by 2
Effects of rTMS in Postpartum Depression: A Meta-Analysis
Wang, T., Wu, H., Jiang, Y., Huang, W. H., Yu, D., Zhang, X., & Mu, Q. (2022) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2022.10.017 · Cited by 2
Petelin, D. S., Bezrukov, V. E., Shishorin, R. M., & Volel, B. A. (2023) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-023-01435-3 · Cited by 2
Kaur, J., & Mania, I. (2019) · Brain stimulation · doi:10.1016/j.brs.2019.03.010 · Cited by 2
Why should we provide transcranial magnetic stimulation (TMS)?
PRIDMORE, S. A., & Pridmore, W. (2019) · Australasian Psychiatry · doi:10.1177/1039856218810152 · Cited by 2
Ahuja, S., Brendle, M., Smart, L., Moore, C., Thielking, P. D., & Robison, R. J. (2022) · Research Square · doi:10.21203/rs.3.rs-1331173/v1 · Cited by 2
Can Deep Brain Stimulation Be a Promising Treatment for Treatment-Resistant Depression?
Nazanin, A., & Ijeuma, N. (2023) · International Journal of Depression and Anxiety · doi:10.23937/2643-4059/1710036 · Cited by 2
Regen, F., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_1 · Cited by 1
Tang, V. M., & Blumberger, D. M. (2024) · Expert Review of Medical Devices · doi:10.1080/17434440.2024.2404962 · Cited by 1
“Some, including major depressive disorder and obsessive-compulsive disorder, are supported by high grade evidence such that they are approved by federal regulatory bodies [15] and recommended by clinical practice guidelines [16,17].”
Dai, H., Hui, J., Wang, D., Ren, L., Lv, Z., Li, J., Yang, Y., Song, J., & Zhang, Z. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.084 · Cited by 1
Ngo, N. L., Asfour, M., Tran, K., Cheung, G., & Mai, T. (2025) · Cureus · doi:10.7759/cureus.77721 · Cited by 1
“The only current FDA-approved use of TMS is for the treatment of major depressive disorder in adults aged 18 and older; however, several studies have investigated its use in both younger and older populations for various applications [20].”
Hui, J., Trevizol, A. P., Espinola, C. W., Kelkar, R. S., Lee, H. H., Mulsant, B. H., Prillo, J., Zomorrodi, R., Zrenner, C., & Blumberger, D. M. (2025) · Transcranial magnetic stimulation . · doi:10.1016/j.transm.2025.100167 · Cited by 2
Atoui, Z., Egan, D., Jha, M. K., Hartwell, K. J., Toll, R. T., Sonne, S. C., Brunner-Jackson, B. M., Subramaniam, G., McCauley, J. L., Trivedi, M. H., et al. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00567-w · Cited by 3
“In the absence of definitive data on the optimal number of rTMS sessions for the treatment of stimulant use disorder, we decided to use 20 to 30 treatment sessions which is considered a standard acute course for the treatment of MDD [34].”
A depression–like phenotype is associated with discrete defects in the primary hippocampal circuit
Gunn, B. G., Yang, C. C., Lauterborn, J. C., Pruess, B. S., Quintanilla, J., Ge, K., Gall, C. M., & LYNCH, G. S. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04094-3 · Cited by 1
Luo, C., He, J., Chang, D., Lan, H., Zhao, M., Zhen, X., Liu, R. P., Bai, L., Li, X. T., Tian, S., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326740 · Cited by 1
Theta burst stimulation (TBS) in methamphetamine use disorder: a meta-analysis and systematic review
Rakesh, G., Adams, T. G., Ballard, D. H., McLouth, C. J., & Rush, C. R. (2025) · Journal of Addictive Diseases · doi:10.1080/10550887.2025.2541165 · Cited by 1
“31 Theta burst stimulation (TBS) is a unique TMS paradigm with theta frequency stimulation nested within gamma frequency to deliver significantly more pulse doses within shorter periods than other repetitive TMS paradigms.”
rTMS treatment for refractory hallucinations: new insights from classic targets
Sommer, I. E., Koops, S., & van den Heuvel, M. P. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00218-4 · Cited by 1
Yang, X.-H., Huang, X., Qin, Z.-J., Ning, Y., & Zheng, W. (2025) · Springer eBooks · doi:10.1007/978-981-96-8504-2_4 · Cited by 2
Neuromodulation for Tourette syndrome: current techniques and future perspectives
Haslam, S., Johnson, K. A., Anderson, D., Mahant, N., & Anderson, C. J. (2025) · Journal of Neural Engineering · doi:10.1088/1741-2552/ae1257 · Cited by 4
“Psychiatric evaluation can lead to a recommendation for therapy by clinical professionals [99–101].”
Mehta, D. D., Sloan, M. E., Sas, A., Freeman, C. R., George, T. P., Selby, P. L., Zawertailo, L. A., Zangen, A., Blumberger, D. M., Foll, B. L., et al. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.10.004 · Cited by 2
薄, 智. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482319 · Cited by 1
Pedroso, I., Saravanan, S. K., Kumbhare, S. V., Sharma, G., Almonacid, D. E., & Sinha, R. (2025) · Healthcare · doi:10.3390/healthcare13233147 · Cited by 2
Barata, P. C., Daftari, B., Pedersen, M. B., & Sack, A. T. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120869 · Cited by 1
Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation
Chen, J. F., Hsu, C.-W., Chen, Y.-T., Fang, Y.-Y., Tseng, P., Chen, M.-H., Yu-Chen, K., Tien-Wei, H., & Liang, C.-S. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121132 · Cited by 3
Lieb, A., Zrenner, B., Becker-Sadzio, J., Gordon, P. C., Kozák, G., Zrenner, C., Martus, P., Ziemann, U., & Fallgatter, A. J. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02176-9 · Cited by 2
“…and treatment parameters [13] Recognizing this heterogeneity, experts emphasize that rTMS protocols should be tailored whenever possible and it is strongly advised that the choice of stimulation site and type is made at a specialized center, which is a level A recommendation [11, 14].”
Викторович, К. Г., Karkashadze, G., Геннадьевна, Н. С., Викторовна, Н. Ю., Михайлович, Я. Л., Ustinova, N. V., & Алексеевна, Г. Е. (2026) · Педиатрическая фармакология · doi:10.15690/pf.v22i6.2987 · Cited by 1
Noda, Y., Osawa, R., Takeda, Y., Fujita, K., Tsuji, T., & Kitahata, R. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16020068 · Cited by 1
“Similarly, antipsychotic or antidepressant co-medication may interact with neuromodulatory mechanisms in ways that alter treatment trajectories [20].”
Metadata
- Authors
- McClintock, S. M., Reti, I. M., Carpenter, L. L., McDonald, W. M., Dubin, M., Taylor, S. F., Cook, I. A., O’Reardon, J., Husain, M. M., Wall, C., Krystal, A. D., Sampson, S. M., Morales, O., Nelson, B. G., Latoussakis, V., George, M. S., Lisanby, S. H., & on behalf of both the National Network of Depression Centers rTMS Task Group and the American Psychiatric Association Council on Research Task Force on Novel Biomarkers and Treatments
- Affiliations
- Duke University (US)
- Johns Hopkins University (US)
- Butler Hospital (US)
- Emory University (US)
- Weill Cornell Medicine (US)
- University of Michigan (US)
- University of California, Los Angeles (US)
- American Psychiatric Association (US)
- Mayo Clinic (US)
- Harvard University (US)
- University of Minnesota (US)
- Medical University of South Carolina (US)
- Corresponding author
- McClintock, Shawn M.
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2018-02-21
- Volume
- 79
- Issue
- 1
- Pages
- 35-48
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC5846193
- OpenAlex
- W2617605873
- Cited by
- 693
- References
- 120
- Citations by year
- 2026: 77 · 2025: 94 · 2024: 108 · 2023: 82 · 2022: 85 · 2021: 98 · 2020: 66 · 2019: 54 · 2018: 22
- FWCI
- 20.18
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR002384)
- National Institute of Mental Health (K23MH087739)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- repetitive transcranial magnetic stimulation, major depressive disorder, depression treatment, expert consensus recommendations, antidepressant treatment
- MeSH terms
- Contraindications, Major Depressive Disorder, Humans, Transcranial Magnetic Stimulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.